Bottom line
IYH vs RXL: the short answer
IYH (iShares U.S. Healthcare ETF) and RXL (ProShares Ultra Health Care) share a meaningful slice of their top holdings — about 73% by weight.
IYH is cheaper at 0.37% vs 0.95% — a difference of $58 a year per $10,000 invested.
Over five years, RXL returned +7.2% a year vs +7.0% for IYH.
Updated Nov 19, 2026
IYH vs RXL side by side
| IYH | RXL | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | ProShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.37% | 0.95% |
| Annual cost per $10k | $37 | $95 |
| 10-yr cost on $10k (prospectus) | $468 | $1,305 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +13.1% | +19.7% |
| 5-yr return (annualized) | +7.0% | +7.2% |
| 10-yr return (annualized) | +9.4% | +12.6% |
| Best quarter | +15.3% | +29.7% |
| Worst quarter | −12.7% | −28.9% |
| Net assets (fund) | $3.6B | $72.1M |
| Number of holdings | 103 | 70 |
| Portfolio turnover | 3% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IYH | RXL | Difference |
|---|---|---|---|
| 2025 | +13.1% | +19.7% | −6.6% |
| 2024 | +3.1% | −2.7% | +5.7% |
| 2023 | +2.1% | −3.2% | +5.2% |
| 2022 | −4.4% | −15.1% | +10.7% |
| 2021 | +23.4% | +47.8% | −24.4% |
| 2020 | +15.5% | +19.2% | −3.8% |
| 2019 | +20.8% | +38.9% | −18.1% |
| 2018 | +5.9% | +5.4% | +0.5% |
| 2017 | +22.3% | +46.0% | −23.7% |
| 2016 | −2.8% | −8.9% | +6.1% |
Source: Fund prospectus bar charts
Holdings overlap
18 of IYH's top 25 holdings also appear in RXL's top 25.
| Holding | IYH | RXL |
|---|---|---|
| Eli Lilly And Company | 15.11% | 12.67% |
| Johnson & Johnson | 10.17% | 7.86% |
| Abbvie Inc. | 7.32% | 5.57% |
| Unitedhealth Group Incorporated | 6.16% | 4.98% |
| Merck & Co., Inc. | 5.31% | 4.26% |
| Thermo Fisher Scientific Incorporated | 3.52% | 2.68% |
| Amgen Inc. | 3.42% | 2.62% |
| Abbott Laboratories | 3.02% | 2.15% |
| Gilead Sciences, Inc. | 2.66% | 2.41% |
| Pfizer Inc. | 2.35% | 2.15% |
| Bristol-myers Squibb Company | 2.20% | 1.68% |
| Intuitive Surgical, Inc. | 2.05% | 2.18% |
| Danaher Corporation | 2.03% | 1.66% |
| Vertex Pharmaceuticals Incorporated | 2.00% | 1.64% |
| Stryker Corporation | 1.86% | 1.52% |
Source: SEC Form N-PORT
IYH top 10
- Eli Lilly And Company — 15.11%
- Johnson & Johnson — 10.17%
- Abbvie Inc. — 7.32%
- Unitedhealth Group Incorporated — 6.16%
- Merck & Co., Inc. — 5.31%
- Thermo Fisher Scientific Incorporated — 3.52%
- Amgen Inc. — 3.42%
- Abbott Laboratories — 3.02%
- Gilead Sciences, Inc. — 2.66%
- Pfizer Inc. — 2.35%
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
FAQ
What is the difference between IYH and RXL?
Which is cheaper, IYH or RXL?
Should I own both IYH and RXL?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.